Cargando…
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient
OBJECTIVE: Juvenile myoclonic epilepsy (JME) is the most common form of idiopathic generalized epilepsies (IGEs) and is genetically heterogeneous. Mutations in EFHC1 cause JME. Because about 2 million people in India are affected by JME alone, we investigated the prevalence of mutations in the EFHC1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939392/ https://www.ncbi.nlm.nih.gov/pubmed/29750216 http://dx.doi.org/10.1002/epi4.12037 |
_version_ | 1783320950709682176 |
---|---|
author | Thounaojam, Romita Langbang, Leader Itisham, Kavish Sobhani, Roohollah Srivastava, Shivani Ramanujam, Bhargavi Verma, Ramesh Tripathi, Manjari Aguan, Kripamoy |
author_facet | Thounaojam, Romita Langbang, Leader Itisham, Kavish Sobhani, Roohollah Srivastava, Shivani Ramanujam, Bhargavi Verma, Ramesh Tripathi, Manjari Aguan, Kripamoy |
author_sort | Thounaojam, Romita |
collection | PubMed |
description | OBJECTIVE: Juvenile myoclonic epilepsy (JME) is the most common form of idiopathic generalized epilepsies (IGEs) and is genetically heterogeneous. Mutations in EFHC1 cause JME. Because about 2 million people in India are affected by JME alone, we investigated the prevalence of mutations in the EFHC1 gene in the Indian population with JME. We studied 63 patients with JME and 80 healthy controls. METHODS: Clinical identification of JME was evaluated using established criteria. Following clinical evaluation of the patients and confirming presence of JME, blood samples were collected from each patient and healthy individual. Subsequently, genomic DNA was extracted from the blood samples. Eleven exons of the EFHC1 gene were individually amplified by polymerase chain reaction (PCR) for each DNA sample. The PCR products were then purified and sequenced commercially. The identified DNA variants were sequenced at least twice in both the forward and reverse directions and compared with the Exome Aggregation Consortium (ExAC) database. RESULTS: We found five heterozygous and one homozygous variant. We found three novel coding variants 661C→T, 779 G →A, and 730 C→T, which lead to R221C, R260Q, and R244STOP amino acid substitutions, respectively. The coding variant 475 C→T, resulting in the amino acid substitution R159W, reported earlier as polymorphism, was also identified in both patient and control populations. SIGNIFICANCE: Detection of these three novel variants, excluding R159W, which is considered polymorphism, expands the range of possible mutations in the EFHC1 gene. The novel variants that we are reporting herein have not been mentioned before as occurring in JME patients of other ethnic population. Therefore, these novel coding variants may be confined to the Indian JME population. Further studies on the mutational spectrum of EFHC1 in a larger number of Indian JME patients concurrent with their mode of inheritance and underlying functional assays should establish whether EFHC1 could be a panethnic gene for JME. |
format | Online Article Text |
id | pubmed-5939392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59393922018-05-10 EFHC1 mutation in Indian juvenile myoclonic epilepsy patient Thounaojam, Romita Langbang, Leader Itisham, Kavish Sobhani, Roohollah Srivastava, Shivani Ramanujam, Bhargavi Verma, Ramesh Tripathi, Manjari Aguan, Kripamoy Epilepsia Open Full‐length Original Research OBJECTIVE: Juvenile myoclonic epilepsy (JME) is the most common form of idiopathic generalized epilepsies (IGEs) and is genetically heterogeneous. Mutations in EFHC1 cause JME. Because about 2 million people in India are affected by JME alone, we investigated the prevalence of mutations in the EFHC1 gene in the Indian population with JME. We studied 63 patients with JME and 80 healthy controls. METHODS: Clinical identification of JME was evaluated using established criteria. Following clinical evaluation of the patients and confirming presence of JME, blood samples were collected from each patient and healthy individual. Subsequently, genomic DNA was extracted from the blood samples. Eleven exons of the EFHC1 gene were individually amplified by polymerase chain reaction (PCR) for each DNA sample. The PCR products were then purified and sequenced commercially. The identified DNA variants were sequenced at least twice in both the forward and reverse directions and compared with the Exome Aggregation Consortium (ExAC) database. RESULTS: We found five heterozygous and one homozygous variant. We found three novel coding variants 661C→T, 779 G →A, and 730 C→T, which lead to R221C, R260Q, and R244STOP amino acid substitutions, respectively. The coding variant 475 C→T, resulting in the amino acid substitution R159W, reported earlier as polymorphism, was also identified in both patient and control populations. SIGNIFICANCE: Detection of these three novel variants, excluding R159W, which is considered polymorphism, expands the range of possible mutations in the EFHC1 gene. The novel variants that we are reporting herein have not been mentioned before as occurring in JME patients of other ethnic population. Therefore, these novel coding variants may be confined to the Indian JME population. Further studies on the mutational spectrum of EFHC1 in a larger number of Indian JME patients concurrent with their mode of inheritance and underlying functional assays should establish whether EFHC1 could be a panethnic gene for JME. John Wiley and Sons Inc. 2017-02-01 /pmc/articles/PMC5939392/ /pubmed/29750216 http://dx.doi.org/10.1002/epi4.12037 Text en © 2016 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Full‐length Original Research Thounaojam, Romita Langbang, Leader Itisham, Kavish Sobhani, Roohollah Srivastava, Shivani Ramanujam, Bhargavi Verma, Ramesh Tripathi, Manjari Aguan, Kripamoy EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title |
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title_full |
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title_fullStr |
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title_full_unstemmed |
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title_short |
EFHC1 mutation in Indian juvenile myoclonic epilepsy patient |
title_sort | efhc1 mutation in indian juvenile myoclonic epilepsy patient |
topic | Full‐length Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939392/ https://www.ncbi.nlm.nih.gov/pubmed/29750216 http://dx.doi.org/10.1002/epi4.12037 |
work_keys_str_mv | AT thounaojamromita efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT langbangleader efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT itishamkavish efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT sobhaniroohollah efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT srivastavashivani efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT ramanujambhargavi efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT vermaramesh efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT tripathimanjari efhc1mutationinindianjuvenilemyoclonicepilepsypatient AT aguankripamoy efhc1mutationinindianjuvenilemyoclonicepilepsypatient |